All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Tumor-associated glycoprotein 72 (TAG-72), also known as CA72-4, is a glycoprotein found on the surface of many cancer cells, including ovary, breast, colon, lung, and pancreatic cancers. It is a mucin-like molecule with a molar mass of over 1000 kDa. TAG-72 is a tumor marker and can be measured with radioimmunoassays like CA 72-4, which uses the monoclonal antibodies indium (111In) satumomab pendetide and iodine (125I) minretumomab. This assay has a good specificity for gastric cancer, with a correlation to the neoplasia's extension. It is used to identify relapses of the disease and to follow up the treatment. TAG-72 is also the target of the anti-cancer drugs anatumomab mafenatox and minretumomab.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-T-1-M325-2 | Anti-TAG-72 scFv h(CD28) CART, pCDCAR1 | Human | CC49 | Humanized | scFv-CD28 | Lentiviral | T cell | ||
CAR-T-1-M325-G | Anti-TAG-72 scFv h(FcεRIγ) CART, pCDCAR1 | Human | CC49 | Humanized | scFv-FcεRIγ | Lentiviral | T cell | ||
CAR-T-1-M325-Z | Anti-TAG-72 scFv h(CD3ζ) CART, pCDCAR1 | Human | CC49 | Humanized | scFv-CD3ζ | Lentiviral | T cell | ||
CAR-T-2-M325-2G | Anti-TAG-72 scFv h(CD28-FcεRIγ) CART, pCDCAR1 | Human | CC49 | Humanized | scFv-CD28-FcεRIγ | Lentiviral | T cell | ||
CAR-T-2-M325-2Z | Anti-TAG-72 scFv h(CD28-CD3ζ) CART, pCDCAR1 | Human | CC49 | Humanized | scFv-CD28-CD3ζ | Lentiviral | T cell | ||
CAR-T-2-M325-4G | Anti-TAG-72 scFv h(CD4-FcεRIγ) CART, pCDCAR1 | Human | CC49 | Humanized | scFv-CD4-FcεRIγ | Lentiviral | T cell | ||
CAR-T-2-M325-4Z | Anti-TAG-72 scFv h(CD4-CD3ζ) CART, pCDCAR1 | Human | CC49 | Humanized | scFv-CD4-CD3ζ | Lentiviral | T cell | ||
CAR-T-2-M325-8Z | Anti-TAG-72 scFv h(CD8-CD3ζ) CART, pCDCAR1 | Human | CC49 | Humanized | scFv-CD8-CD3ζ | Lentiviral | T cell | ||
CAR-T-2-M325-BZ | Anti-TAG-72 scFv h(41BB-CD3ζ) CART, pCDCAR1 | Human | CC49 | Humanized | scFv-41BB-CD3ζ | Lentiviral | T cell | ||
CAR-T-2-M325-CZ | Anti-TAG-72 scFv h(b2c-CD3ζ) CART, pCDCAR1 | Human | CC49 | Humanized | scFv-b2c-CD3ζ | Lentiviral | T cell | ||
CAR-T-3-M325-2BZ | Anti-TAG-72 scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1 | Human | CC49 | Humanized | scFv-CD28-41BB-CD3ζ | Lentiviral | T cell | ||
CAR-T-2-M551-BZ | Anti-TAG-72 (CC49) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | CC49 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-T-2-M551-CZ | Anti-TAG-72 VHH h(b2c-CD3ζ) CAR, [T] | Human | CC49 | Humanized | VHH-b2c-CD3ζ | Lentiviral | T cell | ||
CAR-T-1-M551-2 | Anti-TAG-72 VHH h(CD28) CAR, [T] | Human | CC49 | Humanized | VHH-CD28 | Lentiviral | T cell | ||
CAR-T-3-M551-2BZ | Anti-TAG-72 VHH h(CD28-41BB-CD3ζ) CAR, [T] | Human | CC49 | Humanized | VHH-CD28-41BB-CD3ζ | Lentiviral | T cell | ||
CAR-T-2-M551-2Z | Anti-TAG-72 VHH h(CD28-CD3ζ) CAR, [T] | Human | CC49 | Humanized | VHH-CD28-CD3ζ | Lentiviral | T cell | ||
CAR-T-2-M551-2G | Anti-TAG-72 VHH h(CD28-FcεRIγ) CAR, [T] | Human | CC49 | Humanized | VHH-CD28-FcεRIγ | Lentiviral | T cell | ||
CAR-T-3-M551-2XZ | Anti-TAG-72 VHH h(CD28-OX40-CD3ζ) CAR, [T] | Human | CC49 | Humanized | VHH-CD28-OX40-CD3ζ | Lentiviral | T cell | ||
CAR-T-1-M551-Z | Anti-TAG-72 VHH h(CD3ζ) CAR, [T] | Human | CC49 | Humanized | VHH-CD3ζ | Lentiviral | T cell | ||
CAR-T-2-M551-4Z | Anti-TAG-72 VHH h(CD4-CD3ζ) CAR, [T] | Human | CC49 | Humanized | VHH-CD4-CD3ζ | Lentiviral | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION